|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.72 PLN | -1.30% |
|
-5.00% | -7.88% |
| Apr. 16 | Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Mabion has entered into an agreement with Iceland's LYFIS ehf. for the commercialisation of the former's biosimilar version of Roche (Switzerland)'s MabThera/Rituxan (rituximab), MabionCD20, in Iceland. The agreement, which is to initially span five years with the possibility of renewal, includes registration, sales, and distribution of the biosimilar.
Furthermore, Mabion will receive a share of 50-60% share of the market price on sales.
| 1st Jan change | Capi. | |
|---|---|---|
| -7.88% | 67.97M | |
| -0.49% | 105B | |
| +3.31% | 97.5B | |
| +3.29% | 22.19B | |
| -16.16% | 21.33B | |
| -7.42% | 18.68B | |
| -41.41% | 16.6B | |
| -22.87% | 14.52B | |
| +6.32% | 14.09B | |
| +21.46% | 10.99B |
MABION S.A. 
